{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:37:29Z","timestamp":1793957849253,"version":"4.8.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z181100001718145"],"award-info":[{"award-number":["Z181100001718145"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase use of ICIs, incidence of nirAEs is growing, among which ICI related MG (irMG) is causing high fatality rate. Given the limited evidence, data from a large cohort of patients with irMG is needed to aid in recognition and management of this fatal complication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to summarize clinical characteristics of irMG and explore predictors of irMG clinical outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We summarized our institution's patients who were diagnosed as irMG between Sep 2019 and Oct 2021. We systematically reviewed the literature through Oct 2021 to identify all similar reported patients who met inclusion criteria. As the control group, patients with idiopathic MG were used. We collected data on clinical features, management, and outcomes of both irMG and idioMG cases. Further statistical analysis was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty three irMG patients and 380 idioMG patients were included in the final analysis. For irMG patients, six were from our institution while the rest 57 were from reported cases. The average age of irMG patients is 70.16 years old. Forty three were male. Average time from first ICI injection to symptom onset was 5.500 weeks. Eleven patients had a past history of MG. Higher MGFA classification and higher QMGS rates were observed in irMG patients compared to idioMG patients. For complication, more irMG patients had myositis or myocarditis overlapping compared to idioMG patients. The most commonly used treatment was corticosteroids for both idioMG and irMG. Twenty one patients (35%) with irMG had unfavorable disease outcome. Single variate and multivariate binary logistic regression proved that association with myocarditis, high MGFA classification or QMGS rates at first visit were negatively related to disease outcome in irMG patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>irMG is a life-threatening adverse event. irMG has unique clinical manifestations and clinical outcome compared to idioMG. When suspicious, early evaluation of MGFA classification, QMGS rates and myositis\/myocarditis evaluation are recommended.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.858628","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T07:51:30Z","timestamp":1649317890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Association Between Clinical Factors and Result of Immune Checkpoint Inhibitor Related Myasthenia Gravis: A Single Center Experience and Systematic Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiayu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science (New York, NY)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1759-7714.13266","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system","volume":"11","author":"Shi","year":"2020","journal-title":"Thorac Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","article-title":"Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience","volume":"43","author":"Diamanti","year":"2021","journal-title":"Neurol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100324","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalSci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000001405","article-title":"Refractory nivolumab-induced myasthenia gravis treated with abatacept","author":"Khokher","year":"2021","journal-title":"Am J Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000006278","article-title":"Pearls & Oy-sters: pembrolizumab-induced myasthenia gravis","volume":"91","author":"Algaeed","year":"2018","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/ceo.13499","article-title":"Pembrolizumab-associated ocular myasthenia gravis","volume":"47","author":"Liu","year":"2019","journal-title":"Clin Experiment Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/08998280.2020.1744793","article-title":"Management of immune checkpoint inhibitor-related acute hypoxic neuromuscular respiratory failure using high-flow nasal cannula","volume":"33","author":"Mathews","year":"2020","journal-title":"Proceedings (Baylor University Medical Center)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1702","DOI":"10.7759\/cureus.1702","article-title":"Myasthenia gravis induced by nivolumab: a case report","volume":"9","author":"Mehta","year":"2017","journal-title":"Cureus."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2169\/internalmedicine.1956-18","article-title":"Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy","volume":"58","author":"Onda","year":"2019","journal-title":"Intern Med (Tokyo, Japan)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2324709616674316","DOI":"10.1177\/2324709616674316","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J Investig Med High Impact Case Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/14712598.2021.1897101","article-title":"A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies","volume":"21","author":"Salim","year":"2021","journal-title":"Expert Opin Biol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101145","DOI":"10.1016\/j.eucr.2020.101145","article-title":"Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: a case report","volume":"31","author":"Takai","year":"2020","journal-title":"Urol Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e8757","DOI":"10.1097\/MD.0000000000008757","article-title":"New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: a case report and literature review","volume":"96","author":"Takizawa","year":"2017","journal-title":"Medicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo","year":"2020","journal-title":"IJU Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"omy094","DOI":"10.1093\/omcr\/omy094","article-title":"Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis","volume":"2018","author":"Tozuka","year":"2018","journal-title":"Oxford Med Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/iju5.12132","article-title":"Editorial comment to pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Tomisaki","year":"2020","journal-title":"IJU Case Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1078155220976797","DOI":"10.1177\/1078155220976797","article-title":"Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma","volume":"2020","author":"Dang","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2018","journal-title":"J Oncol Pharm Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcrc.2021.05.020","article-title":"Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: a multi-center case series","volume":"65","author":"Rajendram","year":"2021","journal-title":"J Crit Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2018.10.025","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2217\/imt-2020-0327","article-title":"Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report","volume":"13","author":"Yang","year":"2021","journal-title":"Immunotherapy."},{"key":"B37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/0897190020970750","article-title":"Myasthenia gravis associated with Programmed Death-1 (PD-1) receptor inhibitor pembrolizumab: a 40-day case report","volume":"34","author":"Ziobro","year":"2021","journal-title":"J Pharm Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5126717","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Rep Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13691-020-00408-4","article-title":"Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma","volume":"9","author":"Hayakawa","year":"2020","journal-title":"Int Cancer Conf J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.3390\/ijms22126246","article-title":"Myositis\/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: immune-biological evaluation and case report","volume":"22","author":"Botta","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino","year":"2018","journal-title":"Respirol Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve."},{"key":"B44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e243764","DOI":"10.1136\/bcr-2021-243764","article-title":"Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern","volume":"14","author":"Hajihossainlou","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10072-018-3471-6","article-title":"Ipilimumab treatment associated with myasthenic crises and unfavorable disease course","volume":"39","author":"Derle","year":"2018","journal-title":"Neurol Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve."},{"key":"B52","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve."},{"key":"B54","doi-asserted-by":"publisher","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London, England)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.36.5.729","article-title":"Prednisone-induced worsening of neuromuscular function in myasthenia gravis","volume":"36","author":"Miller","year":"1986","journal-title":"Neurology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5152\/eurjrheum.2019.18159","article-title":"Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma","volume":"6","author":"Sutaria","year":"2019","journal-title":"Eur J Rheumatol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.858628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T07:51:34Z","timestamp":1649317894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.858628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":60,"alternative-id":["10.3389\/fneur.2022.858628"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.858628","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"858628"}}